- Home
- GROV vs NTRB Comparison
GROV vs NTRB Comparison
Compare GROV & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GROV | NTRB |
|---|---|---|
| Founded | 2016 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.1M | 36.0M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GROV | NTRB |
|---|---|---|
| Price | $1.05 | $3.23 |
| Analyst Decision | Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $1.60 | N/A |
| AVG Volume (30 Days) | ★ 25.0K | 5.7K |
| Earning Date | 05-07-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.26 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $173,716,000.00 | $2,036,651.00 |
| Revenue This Year | N/A | $30.17 |
| Revenue Next Year | $6.81 | $3,394.36 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $2.80 |
| 52 Week High | $1.59 | $8.63 |
Technical Indicators
Market Signals| Indicator | GROV | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 43.44 | 63.04 |
| Support Level | $1.06 | $3.21 |
| Resistance Level | $1.17 | $3.44 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 33.33 | 100.00 |
Price Performance
Historical ComparisonAbout GROV Grove Collaborative Holdings Inc.
Grove Collaborative Holdings Inc is a digital-first, sustainability-oriented consumer products innovator specializing in the development and sale of household, personal care, beauty and other consumer products with a human and environmental focus. The Company sells its products through a direct-to-consumer (DTC) platform and the Company's mobile applications, where the Company sells products from Grove-owned brands (Grove Brands) and third-parties.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. Company operates in two reportable segments namely, Sales of Goods and Services. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.